PSMA-targeted radioligand therapy outcomes vary by patient characteristics and disease burden in metastatic castration-resistant prostate cancer
Prior chemo and liver spread worsen outcomes for prostate cancer patients on PSMA therapy
A systematic review and meta-analysis of 4,819 patients with metastatic castration-resistant prostate cancer reveals that prior chemotherapy…
A large review of 4,819 patients found that prior chemotherapy and liver spread worsen survival. This helps doctors predict who benefits mos…
PSMA PET Parameters Predict Survival in mCRPC on Lu-PSMA-617
PSMA PET scan numbers may help predict Lu-PSMA therapy response in prostate cancer
Meta-analysis of 23 studies shows PSMA PET parameters, especially tumor volume, predict survival in mCRPC patients treated with Lu-PSMA-617.
A meta-analysis of 23 studies suggests certain PSMA PET scan measurements might help predict how patients with metastatic prostate cancer re…
Narrative review discusses LPA signaling in advanced prostate cancer
LPA signaling pathway offers new hope for advanced prostate cancer treatment
This narrative review examines lysophosphatidic acid metabolism and signaling in patients with advanced prostate cancer. The authors discuss…
A review discusses how targeting lysophosphatidic acid signaling might help patients with advanced prostate cancer, though more research is …
Enzalutamide plus radium-223 extends survival in metastatic castration-resistant prostate cancer
Adding Radium-223 to enzalutamide extends life for advanced prostate cancer patients
This phase 3 randomized controlled trial in 446 patients with metastatic castration-resistant prostate cancer compared enzalutamide plus rad…
Adding a specific bone-targeting drug to standard treatment helps men with advanced prostate cancer live longer while managing side effects …
EC1169 and 99mTc-EC0652 show increased bone lesion detection and longer rPFS in mCRPC patients
A new prostate cancer drug shows promise but has limited activity in this early trial
This Phase I study evaluated EC1169 and 99mTc-EC0652 in 103 patients with metastatic castration-resistant prostate cancer.
A new prostate cancer drug detected bone lesions better than standard scans and linked to longer survival in early testing.
Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
New drug combo extends life for some prostate cancer patients
This retrospective cohort study of 5 patients with HRR-mutated metastatic castration-resistant prostate cancer evaluated niraparib plus abir…
Some men with advanced prostate cancer are living longer with a powerful new drug combo, even when they’re older or too weak for harsh treat…
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
Meta-analysis associates emerging lesions after lutetium-177 therapy with worse overall survival in mCRPC
Emerging lesions on scans linked to lower survival in prostate cancer patients
This systematic review and meta-analysis evaluated interim post-treatment SPECT/CT findings in 648 patients with metastatic castration-resis…
New spots appearing on scans after treatment for advanced prostate cancer are linked to significantly lower survival rates.
Systematic review of PSMA-directed CAR-T therapy for mCRPC highlights barriers and emerging platforms
New immune cell therapies show promise for advanced prostate cancer
This systematic review examines PSMA-directed CAR-T cell therapy for metastatic castration-resistant prostate cancer.
Engineered immune cells offer new hope for hard-to-treat prostate cancer, but durable responses remain rare.
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression
New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…
Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide
Two Cancer Drugs Teamed Up — Who Actually Benefits Most?
This single-arm, open-label phase 2 trial evaluated olaparib plus durvalumab in 60 men with metastatic castration-resistant prostate cancer …
A new prostate cancer drug combo helped men with specific DNA repair gene variants live more than twice as long without their cancer progres…
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer
FDA approves a new treatment for advanced prostate cancer called Pluvicto
The FDA has approved Pluvicto, a radioligand therapeutic agent, for the treatment of adult patients with PSMA-positive metastatic castration…
FDA approves Pluvicto, a targeted radiation therapy for advanced prostate cancer that has spread and stopped responding to standard hormone …
Research across Metastatic hormone-sensitive prostate cancer
Related studies from across the Metastatic hormone-sensitive prostate cancer family.
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
Synchronous bone-metastatic prostate cancer incidence 6% with median survival of 43 months in Chinese cohort
What happens when prostate cancer spreads to bones at diagnosis?
A retrospective cohort study of patients with synchronous bone-metastatic hormone-sensitive prostate cancer at a Chinese tertiary center fou…
About 6% of men diagnosed with prostate cancer already have it spread to their bones, where high-volume disease doubles the risk of death.
Questions about Metastatic Castration Resistant Prostate Cancer
What barriers exist for using PSMA-directed CAR-T cell therapy to treat my cancer?
PSMA-directed CAR-T therapy for mCRPC faces barriers including a hostile tumor microenvironment, antigen heterogeneity, and T-cell limitations, but new platforms like iPSC-derived CAR-T are being explored.
Full answer →Does finding new lesions after lutetium-177 treatment mean my overall survival will be worse?
Yes, a meta-analysis found that new lesions after lutetium-177 treatment are linked to worse overall survival in mCRPC patients.
Full answer →All Metastatic Castration Resistant Prostate Cancer Articles
- PSMA-targeted radioligand therapy outcomes vary by patient characteristics and disease burden in metastatic castration-resistant prostate cancer
- PSMA PET Parameters Predict Survival in mCRPC on Lu-PSMA-617
- Narrative review discusses LPA signaling in advanced prostate cancer
- Enzalutamide plus radium-223 extends survival in metastatic castration-resistant prostate cancer
- EC1169 and 99mTc-EC0652 show increased bone lesion detection and longer rPFS in mCRPC patients
- Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
- Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
- Meta-analysis associates emerging lesions after lutetium-177 therapy with worse overall survival in mCRPC
- Systematic review of PSMA-directed CAR-T therapy for mCRPC highlights barriers and emerging platforms
- Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression
- FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer
- Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide
- Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
- CDSS Dashboard Implementation Associated with Higher CRPC Detection in Prostate Cancer Cohort
- Phase II study of 177Lu-PSMA-617 in mCRPC shows 50% PSA response and median OS of 18.8 months
- Meta-analysis finds 47% PSA decline >50% with Ac-225/Lu-177 PSMA combination in mCRPC